Infliximab
- 1 June 2001
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 2 (6), 1015-1025
- https://doi.org/10.1517/14656566.2.6.1015
Abstract
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added as efficacy has been proven in fistulising CD and in rheumatoid arthritis. Even though the costs associated with a single dose are several thousand US dollars, more than 150,000 patients have received infusions since its approval.Keywords
This publication has 32 references indexed in Scilit:
- Proinflammatory CytokinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Review article: the clinical role of anti‐TNFα antibody treatment in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2000
- Antibodies to tumour necrosis factor α as treatment for Crohn's diseaseThe Lancet, 2000
- Therapeutic monoclonal antibodiesThe Lancet, 2000
- Role of Cytokines in the Pathogenesis of Inflammatory Bowel DiseaseAnnual Review of Medicine, 2000
- Chemokines and cytokines in inflammatory bowel disease and their application to disease treatmentCurrent Opinion in Gastroenterology, 2000
- Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's diseaseClinical Therapeutics, 1999
- Revisiting the Role of Tumor Necrosis Factor α and the Response to Surgical Injury and InflammationArchives of Surgery, 1998
- Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's diseaseThe Lancet, 1997
- Cytokines in intestinal inflammation: Pathophysiological and clinical considerationsGastroenterology, 1994